久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Realm Therapeutics shares halved after failure of Phase 2 study pharmafile
    August 16, 2018
    Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the experimental drug PR022 had failed to meet its primary endpoint in people with atopic dermatitis.
  • BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy americanpharmaceuticalreview
    May 18, 2018
    Mobilization of hematopoietic stem and progenitor cells (HSPCs) for the purpose of donor (allogeneic) transplantation after high-dose chemotherapy is currently performed using a 4-5 day treatment cycle with G-CSF and a 1-2 day apheresis procedure.
PharmaSources Customer Service